High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

Douglas Gladstone, Marc G. Golightly, Thomas H. Brannagan

Research output: Contribution to journalArticle

Abstract

Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

Original languageEnglish (US)
Pages (from-to)121-126
Number of pages6
JournalJournal of Neuroimmunology
Volume190
Issue number1-2
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Cyclophosphamide
T-Lymphocytes
T-Lymphocyte Subsets
Nervous System
Blood Cells
Lymphocytes
Drug Therapy

Keywords

  • CD4RA+
  • CD4RO+
  • Chronic inflammatory demyelinating polyneuropathy
  • High dose cyclophosphamide
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. / Gladstone, Douglas; Golightly, Marc G.; Brannagan, Thomas H.

In: Journal of Neuroimmunology, Vol. 190, No. 1-2, 10.2007, p. 121-126.

Research output: Contribution to journalArticle

@article{80bdb0dd556f41f5afdefebab35b9a6e,
title = "High dose cyclophosphamide preferentially targets na{\"i}ve T (CD45/CD4/RA+) cells in CIDP and MS patients",
abstract = "Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and na{\"i}ve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, na{\"i}ve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Na{\"i}ve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.",
keywords = "CD4RA+, CD4RO+, Chronic inflammatory demyelinating polyneuropathy, High dose cyclophosphamide, Multiple sclerosis",
author = "Douglas Gladstone and Golightly, {Marc G.} and Brannagan, {Thomas H.}",
year = "2007",
month = "10",
doi = "10.1016/j.jneuroim.2007.07.005",
language = "English (US)",
volume = "190",
pages = "121--126",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients

AU - Gladstone, Douglas

AU - Golightly, Marc G.

AU - Brannagan, Thomas H.

PY - 2007/10

Y1 - 2007/10

N2 - Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

AB - Introduction: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. Method: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. Results: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. Discussion: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.

KW - CD4RA+

KW - CD4RO+

KW - Chronic inflammatory demyelinating polyneuropathy

KW - High dose cyclophosphamide

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=35448938790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448938790&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2007.07.005

DO - 10.1016/j.jneuroim.2007.07.005

M3 - Article

C2 - 17854912

AN - SCOPUS:35448938790

VL - 190

SP - 121

EP - 126

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -